IPO

After a hyped IPO, Black Rock Coffee Bar faces a class action lawsuit as growth slows and its stock plummets. Did the drive-thru darling mislead investors?

With a treasury full of OpenAI equity and the controversial Worldcoin, Eightco (ORBS) offers a risky public market entry into the future of tech.

Spurred by national policy and landmark listings, Japan's innovators are looking to U.S. capital markets for global growth. A new summit maps the path.

A public company is offering a volatile mix of OpenAI, Worldcoin, and MrBeast. We deconstruct the high-risk, high-reward strategy behind its unique treasury.

As First Carolina Bank debuts on the NYSE, its public offering is more than a capital raise—it’s a key indicator of investor faith in regional finance.

With a $150M war chest, E. Scott Crist's latest SPAC hunts for an industrial tech gem. But can a team with a mixed track record deliver in this new era?

Autonomous systems firm INDROTEK signals its IPO ambitions by hiring a strategic communications partner, revealing a plan to master both AI robotics and investor trust.

As tech IPOs stall, a new breed of private credit fund offers a lifeline to employees with 'paper wealth,' unlocking billions in value from top unicorns.

With record AI investment and grand sustainability claims, Ant Group is building the future. But as it pushes into our health and wallets, who truly benefits?

SpaceX's historic IPO wasn't just a launch; it was a market recalibration. We unpack the reality behind the trillion-dollar valuation and what it means for you.

Csquare is going public to fund the AI boom, but its S-1 filing reveals a complex picture of soaring revenue, mounting losses, and significant debt.

Nova Minerals' NYSE debut is more than a stock listing; it's a strategic play at the heart of U.S. national security and the future of critical minerals.

Romanian ad-tech firm Sevio is consolidating the chaotic Web3 ad market, signing deals with giants to offer advertisers unprecedented, transparent access.

Following SpaceX's historic $1.77T IPO, a new ETF offers 2X daily leverage on the stock. But experts warn this high-octane bet is not for everyone.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Ninepoint's new ETF offers Canadians a ticket to the SpaceX growth story, but its leveraged, high-income structure demands a closer look at the risks.

Aya Gold & Silver's inclusion in the GDX Gold Miners ETF marks a major milestone, validating its explosive growth and strategic execution at its Moroccan mines.

Defiance just launched an ETF to short the newly public SpaceX. We dive into the high-stakes gamble on a trillion-dollar titan and the perilous tools of modern trading.

The Defiance 2X Space ETF was halted amidst the SpaceX IPO frenzy, revealing the extreme volatility and complex risks of new leveraged financial products.

A seasoned investment team leaves the world of institutional giants to bring their emerging market strategy to the public through two new actively managed ETFs.